These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 29947795

  • 1. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
    Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F.
    Inflamm Bowel Dis; 2019 Jan 01; 25(1):172-179. PubMed ID: 29947795
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL.
    Clin Gastroenterol Hepatol; 2019 Nov 01; 17(12):2506-2513.e2. PubMed ID: 30630103
    [Abstract] [Full Text] [Related]

  • 4. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, Whiteoak S, Ker S, Perry K, Underhill C, Efrem E, Ahmed I, Cummings F.
    J Crohns Colitis; 2017 Jun 01; 11(6):690-696. PubMed ID: 28130330
    [Abstract] [Full Text] [Related]

  • 5. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR, SECURE study group.
    Lancet Gastroenterol Hepatol; 2018 Jun 01; 3(6):404-412. PubMed ID: 29606564
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.
    J Crohns Colitis; 2022 Sep 08; 16(9):1436-1446. PubMed ID: 35390141
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    Ther Drug Monit; 2019 Jun 08; 41(3):317-324. PubMed ID: 30633088
    [Abstract] [Full Text] [Related]

  • 11. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L, Iglesias Flores E, Benítez JM, Medina Medina R, Salgueiro Rodríguez I, Aguilar Melero P, Cárdenas Aranzana MJ, González Fernández R, Manzanares Martin B, García-Sánchez V.
    Gastroenterol Hepatol; 2017 Nov 08; 40(9):595-604. PubMed ID: 28865888
    [Abstract] [Full Text] [Related]

  • 12. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
    Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML.
    J Crohns Colitis; 2017 Mar 01; 11(3):297-304. PubMed ID: 27660339
    [Abstract] [Full Text] [Related]

  • 13. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL.
    Eur J Gastroenterol Hepatol; 2018 Jul 01; 30(7):699-703. PubMed ID: 29538037
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T.
    Scand J Gastroenterol; 2017 Dec 01; 52(12):1348-1353. PubMed ID: 28838273
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A, Allegretta L, Chiri S, Della Valle N, Elisei W, Forti G, Lorenzetti R, Mocci G, Penna A, Pranzo G, Ricciardelli C, Picchio M.
    Minerva Gastroenterol Dietol; 2017 Dec 01; 63(4):313-318. PubMed ID: 28293938
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R, To N, Gracie DJ, Selinger CP, O'Connor A, Clark T, Carey N, Leigh K, Bourner L, Ford AC, Hamlin PJ.
    Scand J Gastroenterol; 2018 Jun 01; 53(6):700-707. PubMed ID: 29687730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.